Related Experiment Video

Updated: Nov 14, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K

Effects of salvianolate on microcirculatory disturbance in patients with stable coronary heart disease: study

Zhanlu Li1, Yi Luan1, Min Wang1

  • 1Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China.

Trials
|March 9, 2021
PubMed

Insights

This study investigates salvianolate for stable coronary heart disease (CHD) with microcirculatory dysfunction. It aims to confirm salvianolate improves coronary microcirculation in patients with high fractional flow reserve (FFR).

Area of Science:

  • Cardiology
  • Vascular Biology
  • Pharmacology

Background:

  • Coronary microcirculation obstruction leads to myocardial ischemia and poor outcomes.
  • Salvianolate demonstrates cellular cardiovascular protective effects.
  • The impact of salvianolate on stable coronary heart disease (CHD) with high fractional flow reserve (FFR) and microcirculatory disturbances remains unconfirmed.

Purpose of the Study:

  • To evaluate the efficacy of salvianolate in improving coronary microcirculation in patients with stable CHD.
  • To assess the effect of salvianolate on myocardial microcirculatory resistance (IMR) in patients with high FFR.
  • To provide a potential new treatment for stable CHD patients experiencing microcirculatory disturbances.

Main Methods:

  • A randomized controlled trial involving 78 patients with stable coronary disease, high FFR (>0.80), and elevated IMR (>25).
  • Patients were randomized to receive either salvianolate (200 mg IV) or placebo for 7 days.
  • The primary endpoint was the change in IMR after initial treatment; secondary endpoints included angina burden, quality of life, and exercise capacity.

Main Results:

  • The study is designed to measure the change in the index of microcirculatory resistance (IMR) as the primary outcome.
  • Secondary outcomes will assess improvements in Seattle angina scale, quality of life, Holter ECG, and 6-minute walk test.
  • Results are pending completion of the trial and data analysis.

Conclusions:

  • This study is expected to be the first to clarify salvianolate's effect on coronary microcirculation in specific CHD patient populations.
  • Findings may establish salvianolate as an effective therapeutic option for stable CHD with high FFR and microcirculatory impairment.
Abstract

Keywords:
Coronary microcirculationSalvianolate

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
962
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
83
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
471
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
141
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
116
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
89